RT Journal Article
T1 Malignancies in Deceased Organ Donors: The Spanish Experience.
A1 Mahillo, Beatriz
A1 Martin, Silvia
A1 Molano, Esteban
A1 Navarro, Aurora
A1 Castro, Pablo
A1 Pont, Teresa
A1 Andres, Amado
A1 Galan, Juan
A1 Lopez, Montserrat
A1 Oliver, Eva
A1 Martinez, Adolfo
A1 Mosteiro, Fernando
A1 Roque, Rebeca
A1 Perez-Redondo, Marina
A1 Cid-Cumplido, Manuela
A1 Ballesteros, Maria A
A1 Daga, Domingo
A1 Quindos, Brigida
A1 Sancho, Micaela
A1 Royo-Villanova, Mario
A1 Bernabe, Esther
A1 Muñoz, Raul
A1 Chacon, Jose Ignacio
A1 Coll, Elisabeth
A1 Dominguez-Gil, Beatriz
K1 Transplantation
K1 Cholangiocarcinoma
K1 Lung Neoplasms
K1 Transplants
K1 Prostatic Neoplasms
AB To better define the risk of malignancy transmission through organ transplantation, we review the Spanish experience on donor malignancies. We analyzed the outcomes of recipients of organs obtained from deceased donors diagnosed with a malignancy during 2013-2018. The risk of malignancy transmission was classified as proposed by the Council of Europe. Of 10 076 utilized deceased donors, 349 (3.5%) were diagnosed with a malignancy. Of those, 275 had a past (n = 168) or current (n = 107) history of malignancy known before the transplantation of organs into 651 recipients. Ten malignancies met high-risk criteria. No donor-transmitted cancer (DTC) was reported after a median follow-up of 24 (interquartile range [IQR]: 19-25) mo. The other 74 donors were diagnosed with a malignancy after transplantation. Within this group, 64 donors (22 with malignancies of high or unacceptable risk) whose organs were transplanted into 126 recipients did not result in a DTC after a median follow-up of 26 (IQR: 22-37) mo, though a prophylactic transplantectomy was performed in 5 patients. The remaining 10 donors transmitted an occult malignancy to 16 of 25 recipients, consisting of lung cancer (n = 9), duodenal adenocarcinoma (n = 2), renal cell carcinoma (n = 2), extrahepatic cholangiocarcinoma (n = 1), prostate cancer (n = 1), and undifferentiated cancer (n = 1). After a median follow-up of 14 (IQR: 11-24) mo following diagnosis, the evolution was fatal in 9 recipients. In total, of 802 recipients at risk, 16 (2%) developed a DTC, which corresponds to 6 cases per 10 000 organ transplants. Current standards may overestimate the risk of malignancy transmission. DTC is an infrequent but difficult to eliminate complication.
PB Lippincott Williams & Wilkins
YR 2022
FD 2022-01-15
LK http://hdl.handle.net/10668/19871
UL http://hdl.handle.net/10668/19871
LA en
NO Mahíllo B, Martín S, Molano E, Navarro A, Castro P, Pont T, et al. Malignancies in Deceased Organ Donors: The Spanish Experience. Transplantation. 2022 Sep 1;106(9):1814-1823
DS RISalud
RD Jul 4, 2025